+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: NIH/3T3, K562, HT29 and LOVO cell lysates, Primary antibody: P01433(LIPC Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P01433(LIPC Antibody) at dilution 1/120. (Original magnification: ×200)    

  
  

The LIPC gene encodes hepatic lipase (HL), a glycoprotein enzyme primarily synthesized in hepatocytes and involved in lipid metabolism. As a member of the lipase gene family, HL hydrolyzes phospholipids and triglycerides in circulating lipoproteins, playing a critical role in remodeling high-density lipoprotein (HDL) and facilitating cholesterol uptake. Its activity influences plasma HDL-cholesterol levels, linking it to cardiovascular and metabolic disorders. Dysregulated LIPC expression or mutations are associated with altered lipid profiles, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD).

LIPC antibodies are essential tools for detecting and quantifying HL protein expression in research. They enable studies on HL's tissue distribution, enzymatic regulation, and interactions with lipoproteins. Commonly used in techniques like Western blotting, immunohistochemistry (IHC), and ELISA, these antibodies aid in exploring HL's role in lipid homeostasis and its therapeutic potential. Commercial LIPC antibodies are typically raised against specific epitopes of the human protein, ensuring specificity for experimental reproducibility. Recent studies also employ LIPC antibodies to investigate HL's dual role as an enzyme and a ligand in cell signaling, particularly in vascular inflammation and metabolic syndrome. Understanding HL through these antibodies contributes to developing targeted therapies for dyslipidemia and related pathologies.